Your browser doesn't support javascript.
Efficacy and safety of tocilizumab in COVID-19 patients.
Zheng, Kai-Lian; Xu, Ying; Guo, Yu-Feng; Diao, Le; Kong, Xiang-Yu; Wan, Xiao-Jian; Zhao, Feng; Ning, Fang-Zheng; Wang, Li-Bing; Qiao, Fan; Zhao, Jiang-Man; Zhou, Jia-Huan; Zhong, Yue-Qian; Wu, Shou-Xin; Chen, Yi; Jin, Gang; Dong, Yu-Chao.
  • Zheng KL; Department of General Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Xu Y; Huoshenshan Hospital, Wuhan 430100, Hubei, China.
  • Guo YF; Department of Gastroenterology, Hankou Hospital, Wuhan 430000, Hubei, China.
  • Diao L; Huoshenshan Hospital, Wuhan 430100, Hubei, China.
  • Kong XY; Office of Medical Education, Naval Medical University, Shanghai 200433, China.
  • Wan XJ; Shanghai Zhangjiang Institute of Medical Innovation, Shanghai Biotecan Pharmaceuticals Co., Ltd., Shanghai 201204, China.
  • Zhao F; Huoshenshan Hospital, Wuhan 430100, Hubei, China.
  • Ning FZ; Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Wang LB; Huoshenshan Hospital, Wuhan 430100, Hubei, China.
  • Qiao F; Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Zhao JM; Huoshenshan Hospital, Wuhan 430100, Hubei, China.
  • Zhou JH; Department of Cardiovascular Medicine, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Zhong YQ; Department of General Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Wu SX; Huoshenshan Hospital, Wuhan 430100, Hubei, China.
  • Chen Y; Department of Hematology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Jin G; Huoshenshan Hospital, Wuhan 430100, Hubei, China.
  • Dong YC; Department of Cardiac Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Aging (Albany NY) ; 12(19): 18878-18888, 2020 Oct 08.
Article in English | MEDLINE | ID: covidwho-841406
ABSTRACT
In this retrospective study we assessed the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19). We enrolled 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with confirmed COVID-19 between January 2020 and February 2020. Ninety-two patients were treated with tocilizumab, and 89 patients were treated conventionally. We analyzed the clinical manifestations, changes in CT scan images, and laboratory tests before and after tocilizumab treatment, and compared these results with the conventionally treated group. A significant reduction in the level of C-reactive protein was observed 1 week after tocilizumab administration. In some cases this meant the end of the IL-6-related cytokine storm. In addition, tocilizumab relieved fever, cough, and shortness of breath with no reported adverse drug reactions. These findings suggest tocilizumab improves clinical outcomes and is effective for treatment of patients with critical or severe COVID-19. However, future clinical trials are needed to better understand the impact of tocilizumab interference with IL-6 and provide a therapeutic strategy for treatment of COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Aging (Albany NY) Journal subject: Geriatrics Year: 2020 Document Type: Article Affiliation country: Aging.103988

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Aging (Albany NY) Journal subject: Geriatrics Year: 2020 Document Type: Article Affiliation country: Aging.103988